Sellas Life Sciences Group I
SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.
NASDAQ
SLS
1 article
$3.1B Market cap · 2026-08-24
SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.